Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID)

MLA

Marion Haubitz, et al. “Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: Results from a German Registry (GRAID).” The Journal of Rheumatology, vol. 39, Sept. 2012, pp. 2153–56. EBSCOhost, https://doi.org/10.3899/jrheum.120482.

APA

Marion Haubitz, Falk Hiepe, Stefan Heitmann, Eva Ostermeier, Julia Holle, Rebecca Fischer-Betz, Svjetlana Lovric, Jörg Henes, Gerd-Rüdiger Burmester, Raoul Bergner, Petra Roll, Thomas Dorner, Martin Aringer, Christof Specker, Andrea Rubbert-Roth, L. Unger, Hans-Peter Tony, Ulf Müller-Ladner, Hendrik Schulze-Koops, … Ina Kötter. (2012). Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID). The Journal of Rheumatology, 39, 2153–2156. https://doi.org/10.3899/jrheum.120482

Chicago

Marion Haubitz, Falk Hiepe, Stefan Heitmann, Eva Ostermeier, Julia Holle, Rebecca Fischer-Betz, Svjetlana Lovric, et al. 2012. “Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: Results from a German Registry (GRAID).” The Journal of Rheumatology 39 (September): 2153–56. doi:10.3899/jrheum.120482.